Discounted Cash Flow Rating

Neutral

Return on Equity Rating

Strong Sell

Debt to Equity Rating

Neutral

Price to Earnings Rating

Strong Buy

Analyst Rating

Neutral

Simple Moving Average

Neutral

Exponential Moving Average

Neutral

Relative Strength Index

Buy

Standard Deviation

Neutral

Williams %R

Strong Buy

Average Directional Index

Strong Sell

Insider Trading

Strong Buy

Wall Street Data Solutions Rating

Neutral

B

Corvus Pharmaceuticals, Inc. (CRVS)

Pharmaceutical Preparations

https://www.corvuspharma.com

Corvus Pharmaceuticals Inc is a clinical-stage biopharmaceutical engaged in developing drugs and antibodies that target the most critical cellular elements of the immune system. It focuses on the development of immune modulator product candidates to treat COVID-19, T-cell lymphomas, other cancers and autoimmune diseases. The company's lead product candidate is CPI-006 which is a potent humanized monoclonal antibody that is designed to react with a specific site on CD73. Its other product candidates are CPI-818, CPI-935, CPI-182 and Ciforadenant.

863 MITTEN ROAD, SUITE 102
BURLINGAME, CA

Current Price

---.--

% Change Today

0.00%

Change Amt. Today

0.00

Active Status

Active

Listing Date

03/23/2016

Market Cap

243,324,557

Shares Outstanding

49,040,000

Weighted SO

49,038,582

Total Employees

N/A

Upcoming Earnings

08/13/2024

Similar Tickers

MREO --.--%

MREO --.--%

TERN --.--%

TERN --.--%

PDSB --.--%

PDSB --.--%

INZY --.--%

INZY --.--%

HOOK --.--%

Beta

1.1020

Last Div

0.0000

Range

1.05-4.04

Chg

0.0900

Avg Vol

239079

Mkt Cap

243324557

Exch

NASDAQ

Country

US

Phone

650 900 4520

DCF Diff

3.6844

DCF

0.2342

Div Yield

0.0000

P/S

989.1242

EV Multiple

-9.8375

P/FV

4.5343

Div Yield %

0.0000

P/E

-10.2703

PEG

-0.2133

Payout

0.0000

Current Ratio

3.6189

Quick Ratio

3.6189

Cash Ratio

1.1129

DSO

181.0163

DIO

0.0000

Op Cycle

181.0163

DPO

4340.6373

CCC

-4159.6210

Gross Margin

0.5854

Op Margin

-95.1179

Pretax Margin

-91.9350

Net Margin

-91.9350

Eff Tax Rate

0.0239

ROA

-0.3503

ROE

-0.5399

ROCE

-0.4568

NI/EBT

1.0000

EBT/EBIT

0.9665

EBIT/Rev

-95.1179

Debt Ratio

0.0217

D/E

0.0273

LT Debt/Cap

0.0135

Total Debt/Cap

0.0266

Int Coverage

-15.0476

CF/Debt

-15.1707

Equity Multi

1.2603

Rec Turnover

2.0164

Pay Turnover

0.0841

Inv Turnover

0.0000

FA Turnover

0.3195

Asset Turnover

0.0038

OCF/Share

-0.3557

FCF/Share

-0.3557

Cash/Share

0.7913

OCF/Sales

-86.3374

FCF/OCF

1.0000

CF Coverage

-15.1707

ST Coverage

-30.3414

CapEx Coverage

0.0000

Div&CapEx Cov

0.0000

P/BV

4.5343

P/B

4.5343

P/S

989.1242

P/E

-10.2703

P/FCF

-11.4565

P/OCF

-10.9362

P/CF

-10.9362

PEG

-0.2133

P/S

989.1242

EV Multiple

-9.8375

P/FV

4.5343

DPS

0.0000

Latest Headlines (EST)

GlobeNewswire Inc. Nov 09, 18:40 Corvus Pharmaceuticals Announces New Data Highlighting Potential of Ciforadenant to Overcome Immunotherapy Resistance in Metastatic Castration Resistant Prostate Cancer GlobeNewswire Inc. Dec 09, 12:00 Corvus Pharmaceuticals Presents New Interim Soquelitinib Data from its Phase 1/1b T Cell Lymphoma Trial GlobeNewswire Inc. Dec 09, 12:00 Corvus Pharmaceuticals Presents New Interim Soquelitinib Data from its Phase 1/1b T Cell Lymphoma Trial GlobeNewswire Inc. Dec 09, 12:00 Corvus Pharmaceuticals Presents New Interim Soquelitinib Data from its Phase 1/1b T Cell Lymphoma Trial GlobeNewswire Inc. Dec 09, 12:00 Corvus Pharmaceuticals Presents New Interim Soquelitinib Data from its Phase 1/1b T Cell Lymphoma Trial GlobeNewswire Inc. Nov 02, 09:15 Corvus Pharmaceuticals to Present New Interim Soquelitinib Data from its Phase 1/1b T Cell Lymphoma Trial at the 65th American Society of Hematology (ASH) Annual Meeting & Exposition GlobeNewswire Inc. Nov 01, 19:31 Corvus Pharmaceuticals Announces Publication of Preclinical Data Demonstrating Potential of ITK Inhibition with Soquelitinib as a Novel Approach to T Cell-Mediated Inflammatory and Immune Diseases GlobeNewswire Inc. Nov 01, 19:31 Corvus Pharmaceuticals Announces Publication of Preclinical Data Demonstrating Potential of ITK Inhibition with Soquelitinib as a Novel Approach to T Cell-Mediated Inflammatory and Immune Diseases GlobeNewswire Inc. Nov 01, 19:31 Corvus Pharmaceuticals Announces Publication of Preclinical Data Demonstrating Potential of ITK Inhibition with Soquelitinib as a Novel Approach to T Cell-Mediated Inflammatory and Immune Diseases GlobeNewswire Inc. Nov 01, 19:31 Corvus Pharmaceuticals Announces Publication of Preclinical Data Demonstrating Potential of ITK Inhibition with Soquelitinib as a Novel Approach to T Cell-Mediated Inflammatory and Immune Diseases

Revenue Product Segmentation